Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ACIU

AC Immune SA

Apr 16 • 04:00PM ET

3.07

-0.07 -2.23 %

Healthcare • Biotechnology • Switzerland • NASD

Peers: BIIB LLY SNY PRTA QURE FLNA ABEO ANVS AXSM INMB

| Held by: IBB DFAS DFMC DFAU DFAC DCOR IBBQ BIB DXUV IBRN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.84	Insider Own	38.57%	Shs Outstand	101.74M	Perf Week	-9.71%
Market Cap	312.44M	Forward P/E	4.83	EPS next Y	0.64	Insider Trans	0.00%	Shs Float	62.52M	Perf Month	-7.53%
Enterprise Value	202.79M	PEG	-	EPS next Q	-0.19	Inst Own	25.45%	Short Float	4.74%	Perf Quarter	-16.35%
Income	-84.59M	P/S	73.00	EPS this Y	51.17%	Inst Trans	1.95%	Short Ratio	9.93	Perf Half Y	0.00%
Sales	4.28M	P/B	5.51	EPS next Y	245.57%	ROA	-37.64%	Short Interest	2.96M	Perf YTD	-2.23%
Book/sh	0.56	P/C	2.71	EPS next 5Y	-	ROE	-93.71%	52W High	4.00 -23.25%	Perf Year	104.67%
Cash/sh	1.13	P/FCF	-	EPS past 3/5Y	1.71% 1.71%	ROIC	-137.98%	52W Low	1.45 111.72%	Perf 3Y	37.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	1.45% -23.52%	Gross Margin	-	Volatility	5.41% 7.49%	Perf 5Y	-54.38%
Dividend TTM	-	EV/Sales	47.38	EPS Y/Y TTM	-46.04%	Oper. Margin	-1935.02%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.02	Sales Y/Y TTM	-86.41%	Profit Margin	-1977.86%	RSI (14)	51.74	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.02	EPS Q/Q	1.33%	SMA20	3.49%	Beta	1.70	Target Price	8.91
Payout	-	Debt/Eq	0.10	Sales Q/Q	-67.36%	SMA50	4.60%	Rel Volume	1.98	Prev Close	3.14
Employees	122	LT Debt/Eq	0.08	Earnings	Mar 13 BMO	SMA200	7.77%	Avg Volume	298.60K	Price	3.07
IPO	Sep 23, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.65% -56.92%	Trades		Volume	580,455	Change	-2.23%

Date	Action	Analyst	Rating Change	Price Target Change
May-31-24	Initiated	BTIG Research	Buy	$8
Feb-01-19	Downgrade	UBS	Buy → Neutral
Jan-04-19	Initiated	UBS	Buy
Apr-05-18	Initiated	H.C. Wainwright	Buy	$18
Mar-23-18	Downgrade	Credit Suisse	Outperform → Neutral
Oct-18-16	Initiated	Leerink Partners	Outperform
Oct-18-16	Initiated	Jefferies	Buy	$25
Oct-18-16	Initiated	Credit Suisse	Outperform	$18

Apr-09-26 08:01PM	Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year? (Quartz) +5.92%
Apr-07-26 07:00AM	AC Immune Announces Amendment to Morphomer Tau License and Collaboration Agreement with Lilly (GlobeNewswire) +15.19%
Mar-19-26 07:00AM	AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 (GlobeNewswire)
Mar-13-26 07:11AM	AC Immune: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
07:00AM	Loading…
Mar-05-26 07:00AM	AC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD 2026 (GlobeNewswire)
Feb-24-26 07:00AM	AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor (GlobeNewswire) +7.51%
Feb-20-26 05:23AM	Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi (BioPharma Dive)
Dec-26-25 10:00AM	Startup Lifordi Seeks to Deliver Potent Medication for Autoimmune Diseases (The Wall Street Journal)
Dec-11-25 08:36AM	AC Immune posts positive data for Parkinsons immunotherapy (BioPharma Dive) +15.41%
07:00AM	AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease (GlobeNewswire)
Nov-11-25 07:00AM	AC Immune to Present at the Jefferies 2025 London Healthcare Conference (GlobeNewswire)
Nov-04-25 08:55AM	AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:48AM	AC Immune: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
10:00AM	Loading…
Oct-29-25 10:00AM	Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) +9.09%
Oct-28-25 10:00AM	Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline (Zacks)
07:00AM	AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board (GlobeNewswire)
Oct-24-25 08:50AM	First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine (GlobeNewswire) +15.66%
Oct-09-25 09:23AM	Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? (Zacks)
Sep-25-25 07:00AM	Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine (GlobeNewswire) +6.59%
Sep-04-25 03:45AM	AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway (GlobeNewswire)
Aug-06-25 06:56AM	New Strong Sell Stocks for August 6th (Zacks) -11.43%
Aug-05-25 08:15AM	AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +11.62%
07:21AM	AC Immune: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-30-25 10:00AM	Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? (Zacks) -7.23%
Jul-29-25 10:00AM	AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Apr-30-25 08:15AM	AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:15AM	AC Immune: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-03-25 09:46AM	AC Immune reports interim outcomes from trial of Parkinsons therapy (Clinical Trials Arena) -5.85%
Apr-02-25 06:00AM	AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease (GlobeNewswire)
Mar-25-25 07:00AM	AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD 2025 (GlobeNewswire) -6.60%
Mar-24-25 03:00PM	ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? (Zacks)
Mar-13-25 07:00AM	AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Mar-05-25 12:00PM	AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +6.38%
Mar-04-25 07:00AM	AC Immune to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-13-25 09:35AM	Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) (Zacks) +10.74%
Dec-11-24 07:26AM	AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2 (TipRanks)
Dec-10-24 07:00AM	AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome (GlobeNewswire)
Nov-15-24 12:33PM	AC Immunes stock jumps after Parkinsons therapy shows signs of benefit (Pharmaceutical Technology) -10.14%
07:30AM	AC Immune reports interim results from Phase 2 trial of ACI-7104.056 (TipRanks)
Nov-14-24 07:00AM	AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease (GlobeNewswire) +13.42%
Nov-13-24 07:00AM	AC Immune to Present at the Jefferies 2024 London Healthcare Conference (GlobeNewswire)
Nov-05-24 07:30AM	AC Immune: Q3 Earnings Snapshot (Associated Press Finance) +10.20%
07:00AM	AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-23-24 09:12AM	What To Expect From AC Immune SA (ACIU) Q3 2024 Earnings (GuruFocus.com)
Sep-17-24 07:00AM	AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease (GlobeNewswire) +5.81%
Aug-29-24 07:13AM	FDA grants fast track designation to Life Molecular Imagings tau PET diagnostic (Medical Device Network)
Aug-28-24 09:00AM	AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions (GlobeNewswire)
Aug-06-24 09:25AM	AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:23AM	AC Immune: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-31-24 08:30AM	AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 (GlobeNewswire)
Jul-25-24 12:53PM	AC Immune wins FDA fast track for Alzheimers vaccine (Pharmaceutical Technology) +10.76%
07:00AM	AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease (GlobeNewswire)
Jul-16-24 07:00AM	AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 (GlobeNewswire) +5.15%
May-28-24 07:00AM	AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 (GlobeNewswire) +9.32%
May-13-24 03:58PM	Sector Update: Health Care Stocks Mixed Late Afternoon (MT Newswires) +42.86%
03:37PM	Sector Update: Health Care (MT Newswires)
02:53PM	ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024 (InvestorPlace)
02:41PM	Top Midday Gainers (MT Newswires)
11:22AM	Takeda shells out $100m to license AC Immunes Phase II Alzheimers therapy (Pharmaceutical Technology)
08:13AM	Why Is AC Immune (ACIU) Stock Up 45% Today? (InvestorPlace)
08:02AM	Takeda nabs option to license Alzheimers immunotherapies from AC Immune (BioPharma Dive)
08:00AM	Top Premarket Gainers (MT Newswires)
07:26AM	Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate (MT Newswires)
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:12AM	AC Immune: Q1 Earnings Snapshot (Associated Press Finance)
06:05AM	AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
06:00AM	AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimers Disease (Business Wire)
05:52AM	Takeda pays AC Immune $100M upfront for Alzheimer's drug as phase 2 readout nears (FierceBiotech.com)
Mar-14-24 10:52PM	ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.00% +5.11%
07:00AM	AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-22-24 07:00AM	AC Immune Announces Upcoming Presentations at AD/PD 2024 (GlobeNewswire)
Feb-21-24 11:16AM	5 Little-Known Penny Stocks With Massive Upside Potential (Insider Monkey)
Jan-30-24 09:35AM	Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround (Zacks)
Jan-22-24 08:48AM	Roche's Genentech returns Alzheimer's assets to AC Immune, cutting 18-year tie to the biotech (FierceBiotech.com)
07:00AM	AC Immune to Regain Global Rights to Crenezumab and Semorinemab (GlobeNewswire)
Jan-18-24 12:00PM	AC Immune (ACIU) is a Great Momentum Stock: Should You Buy? (Zacks)
Jan-03-24 12:00PM	AC Immune (ACIU) Upgraded to Buy: Here's Why (Zacks)
08:10AM	AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases (GlobeNewswire)
Dec-15-23 07:56AM	AC Immune Announces Pricing of Underwritten Offering of Common Shares (GlobeNewswire) +5.66%
07:22AM	AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial (GlobeNewswire)
Dec-05-23 05:59AM	Is it a Good Idea to Invest in AC Immune (ACIU) Stock Now? (Zacks)
Dec-01-23 07:00AM	AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO (GlobeNewswire)
Nov-28-23 07:33PM	Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth (InvestorPlace) +7.02%
Nov-20-23 06:00AM	FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug success (Reuters)
Nov-07-23 07:00AM	AC Immune to Present at the Jefferies 2023 London Healthcare Conference (GlobeNewswire)
Nov-03-23 08:37AM	AC Immune: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-02-23 07:00AM	AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023 (GlobeNewswire)
Oct-27-23 07:00AM	AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic (GlobeNewswire) -6.55%
Oct-24-23 09:40AM	Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year? (Zacks) +5.66%
Oct-23-23 10:00AM	Earnings Preview: Qiagen (QGEN) Q3 Earnings Expected to Decline (Zacks) +7.72%
Oct-20-23 10:00AM	AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks) -11.19%
Oct-18-23 08:26AM	NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock? (Zacks)
Oct-17-23 07:00AM	AC Immune Announces Upcoming Presentations at the 16th CTAD Conference (GlobeNewswire)
Oct-05-23 07:00AM	AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 (GlobeNewswire)

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eliseev on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
ANDREA M.A PFEIFER	Officer	Apr 15 '26	Proposed Sale	3.19	10,000	31,900	Apr 15 04:52 PM
ANDREA M.A PFEIFER	Officer	Jan 15 '26	Proposed Sale	3.67	30,000	110,100	Jan 15 04:25 PM
ANDREA M.A PFEIFER	Officer	Oct 03 '25	Proposed Sale	3.13	45,000	140,850	Oct 03 04:28 PM
ANDREA M.A PFEIFER	Officer	Sep 12 '25	Proposed Sale	2.38	35,000	83,300	Sep 12 04:41 PM
ANDREA M.A PFEIFER	Officer	Jul 24 '25	Proposed Sale	2.34	20,000	46,800	Jul 24 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ACIU

AC Immune SA

Upgrade your Finviz experience